株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

夜間頻尿 : パイプライン分析

Nocturia - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 213118
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
夜間頻尿 : パイプライン分析 Nocturia - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 43 Pages
概要

夜間頻尿は、夜間に最低2回は排尿のために起床しなければならない症状、と定義されています。男女とも年齢を重ね、また様々な理由により、この症状を発症するようになります。夜間頻尿の主な要因として、うっ血性心不全や下肢浮腫、睡眠障害(閉塞型睡眠時無呼吸など)、一部の医薬品(利尿剤、強心性配糖体、リチウム、メトキシフルラン、フェニトイン、プロポキシフェン、ビタミンD過剰摂取など)、睡眠前の水分の過剰摂取(特にコーヒーやカフェイン入り飲料、アルコールほか)などが挙げられます。主な治療法には抗コリン剤療法などがあります。

当レポートでは、世界各国での夜間頻尿治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

夜間頻尿の概要

治療薬の開発

  • 夜間頻尿向けパイプライン製品:概要
  • 夜間頻尿向けパイプライン製品:比較分析

各企業で開発中の夜間頻尿治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

夜間頻尿治療薬:開発中の製品の一覧(企業別)

夜間頻尿治療薬の開発に従事している企業

  • Allergan, Inc.
  • Ferring International Center S.A.
  • 大日本住友製薬
  • Vantia Therapeutics

夜間頻尿:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • afacifenacin
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ASP-7035
  • 酢酸デスモプレシン
  • FE-999309
  • fedovapagon
  • Paxerol

夜間頻尿治療薬:パイプライン製品の最新動向

夜間頻尿治療薬:開発が休止状態の製品

夜間頻尿関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Nocturia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Nocturia - Pipeline by Ferring International Center SA, H2 2019
  • Nocturia - Pipeline by Roivant Sciences Ltd, H2 2019
  • Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
  • Nocturia - Pipeline by Vantia Ltd, H2 2019
  • Nocturia - Dormant Projects, H2 2019
  • Nocturia - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Nocturia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11388IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H2 2019, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.

Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs, including diuretics (water pills), cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin d and drinking too much fluid before bedtime, especially coffee, caffeinated beverages, or alcohol. Treatment includes anticholinergic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nocturia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 2 and 4 respectively.

Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Nocturia - Overview
    • Nocturia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
    • Nocturia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nocturia - Companies Involved in Therapeutics Development
    • Ferring International Center SA
    • Roivant Sciences Ltd
    • Sanwa Kagaku Kenkyusho Co Ltd
    • Vantia Ltd
  • Nocturia - Drug Profiles
    • (acetaminophen + ibuprofen) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • desmopressin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FE-201836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fedovapagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1404 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nocturia - Dormant Projects
  • Nocturia - Discontinued Products
  • Nocturia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 07, 2019: Avadel expects to realize $70 to $75 million in cost reductions in 2019 by exiting NOCTIVA
      • Oct 29, 2018: Avadel presents data on Quality of Life Improvement in patients on NOCTIVA at American Urological Association Western Annual Meeting
      • Oct 15, 2018: Avadel Pharmaceuticals presents data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting
      • Sep 28, 2018: Avadel Pharmaceuticals announces Journal of Urology Publication of phase 3 data on NOCTIVA
      • Aug 29, 2018: New Data on NOCTIVA Presented at the 2018 International Continence Society Meeting
      • May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting
      • May 01, 2018: Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
      • Apr 03, 2018: Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA at the 2018 American Urological Association
      • Oct 05, 2017: Avadel Pharmaceuticals Announces Data Presentation for Noctiva at The American Urogynecologic Societys Annual Scientific Meeting
      • Oct 20, 2016: FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)
      • May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia
      • May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top